Why better change communication matters for Talking Medicines’ workplace positioning

Tern plc

Talking Medicines is using a familiar workplace challenge to sharpen the case for its employee insight offering. In its latest commentary on change communication, the company focuses on a problem that remains highly relevant for employers: as organisations move through repeated rounds of transformation, the volume of internal messaging rises, but clarity does not always keep pace.

New technologies, changing work models and shifting business priorities are creating an environment in which employees are regularly asked to adapt. Against that backdrop, Talking Medicines argues that communication has become a critical management function, not simply an administrative task.

It places the company’s PeopleVoice proposition in a category linked to execution risk inside large organisations. If change programmes are poorly understood, businesses can face slower adoption, weaker engagement and reduced confidence among staff. By aligning its offer with that pressure point, Talking Medicines is presenting its technology as part of the infrastructure needed to support organisational change more effectively.

Tern plc (LON:TERN) backs exciting, high growth IoT innovators in Europe. They provide support and create a genuinely collaborative environment for talented, well-motivated teams.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Tern Plc reports 2025 results and outlines portfolio value strategy

Tern plc has reported audited annual results, outlined portfolio developments and convened a General Meeting for 9 July 2026.

Device Authority targets enterprise IoT security demand through Xalient partnership

Device Authority has partnered with Xalient to bring KeyScaler into managed enterprise security services, strengthening its position in scalable IoT and OT device identity management.

Talking Medicines targets a clearer view of GLP-1 and cancer care demand

Talking Medicines is showing why real-world healthcare conversations matter for investors tracking GLP-1, oncology and the next stage of life sciences market positioning.

GLP-1 cancer signals add a new investor angle

Early oncology signals from ASCO 2026 add a new investor angle to the GLP-1 story, with further research needed before clinical or commercial conclusions can be drawn.

Device Authority expands enterprise reach through IoT security partnership

Device Authority’s partnership with Xalient strengthens its enterprise IoT security positioning as regulated industries look for scalable, automated ways to manage connected device risk.

Pharma engagement shifts from reach to relevance

Pharma engagement is moving from broad reach to relevant messaging across connected patient journeys.

Search